ARHGEF4 and colorectal carcinoma: Especially, KRAS showed reduced expression and ARHGEF4 showed elevated expression in HCT116 DKO as a consequence of DNMT inhibition, consistent with the hypermethylated DMRs we observed in the gene body and promoter regions of KRAS and ARHGEF4, respectively in CRC.